bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

bioAffinity Technology reported continued acceleration in commercial sales for its CyPath® Lung diagnostic, with more than 200% year-over-year growth. The update signals improving commercial traction, but no profitability, guidance, or market-size metrics were provided.

Analysis

bioAffinity Technology reported continued acceleration in commercial sales for its CyPath® Lung diagnostic, with more than 200% year-over-year growth. The update signals improving commercial traction, but no profitability, guidance, or market-size metrics were provided.